ARS Pharmaceuticals, Inc. (NASDAQ:SPRY – Get Free Report) has earned a consensus recommendation of “Buy” from the seven research firms that are currently covering the stock, Marketbeat Ratings reports ...
Oppenheimer initiated coverage of ARS Pharmaceuticals (SPRY) with an Outperform rating and $40 price target As the first and only approved ...
SAN DIEGO, Jan. 21, 2025 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect ...
Highlights,ARS Pharmaceuticals (SPRY) has received favorable market target projections from research experts.,Significant ...
After hours: February 13 at 5:27:47 PM EST Loading Chart for SPRY ...
Hosted on MSN14h
Pfizer’s Talzenna gains 14-months OS lead over mCRPC SoCResults from the company’s Talapro-2 trial saw a 38% reduction in the risk of death among HRR-mutated patients.
After hours: 8 January at 6:29:23 pm GMT-5 ...
But the fact that DOGE aides are reportedly working in the offices of Medicaid and even Medicare—where budget cuts have been ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback